Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)
French National Agency for Research on AIDS and Viral Hepatitis
This date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reported
Study Completion
January 2006
Date type not reported
This date has not been verified as actual or estimated.
Brief Summary
This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy. Efficacy is assessed by the complete response rate at day 60. The patients are followed until day 365.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Recruitment status
terminated
Reported enrollment (type unavailable)
25 participants
Study completion date
January 2006
Date type not reported
This date has not been verified as actual or estimated.
Listed locations
0 countries · 0 sites
Trial Relationships
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Related Scientific Literature
Loading related publications...
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
Study Start
May 2003
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
August 4, 2005
Actual (reported)
First Posted
August 8, 2005
Actual (reported)
Study Completion
January 2006
Date type not reported
This date has not been verified as actual or estimated.
Ongoing highly active antiretroviral therapy (HAART) for at least 3 months
No threshold of CD4 cell count and HIV-RNA
Signed written informed consent
You may not qualify if:
Prior treatment with rituximab
Evolutive lymphoma or Kaposi's sarcoma needing treatment
Absence of effective contraception
Pregnancy
Contact the study team to confirm eligibility.
Urogenital Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Hemic and Lymphatic Diseases
Immunoproliferative Disorders
Herpesviridae Infections
DNA Virus Infections
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Vascular Tissue
Intervention Hierarchy (Ancestors)
Antibodies, Monoclonal, Murine-DerivedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins
This date has not been verified as actual or estimated.
Last Updated
January 12, 2007
Record last verified: 2007-01
Source record
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.